Hey guys, SEATTLE GENETICS is on a bullish slant, if we breakout from the equilibrium zone and go over half of the next one then we could get to the top of this one.
Please LIKE & FOLLOW, thank you!
Cleaning up Watch List: went through stocks my students were interested ...very impressive selections...re-evaluating the charting>>>suggesting a strategy that may appeal to high net-worth individuals concerned about capital gains.
5.19.20 I thought I would compare how I might analyze a market and frame a trade differently than an imaginary advisory service. It's not just about the accuracy of the trades, but the time it would take me, and the energy it would take me to work the trade because this matters. Even a good analysis might take much more time and energy and stress than some...
SGEN Part 3 Listen to all three parts ( twice ). Try to replicate some of the lines. I am 100% certain that you will miss parts of it. Don't worry, and expect even the simplest thing, drawing arrange box, is different for me than it is for you when your first doing this. Don't worry. Even a simple range box may take you a couple weeks to get familiar and more...
#SeattleGenetics is doing several impressive studies which helped stock price moved up.They stayed strong during the crash. It is doing well so far but it may stall for a while because of the coming resistances.
This dropped off the bull flag today on no news. Technically, everything looks solid. So only conclusion I can make is that big guys want it cheaper so they did. This goes back up tomorrow bigly. Check those levels.
gl
This is just garbage. Sitting here a bubbly parabolic ATH's. This is the #1 short on the planet right now. Overbought on the fucking weekly now in both RSi and MFI. The top is in.
Hello Traders!
It looks like $SGEN has made a local top and will be headed for consolidation. Not to worry, I believe continued upside potential is favored. My plan includes stacking buy orders at $90-$75 with stops at $70. Do your own DD, and good luck!
Yo boy,
Pic
Another upgrade on back of positive Breast treatment trial.
Analyst upgrade
H.C. Wainwright analyst Andrew Fein raised his price target for Seattle Genetics to $140 from $98 and reiterates a Buy rating on the shares. The "remarkable" HER2CLIMB topline results position Seattle Genetics "as a strong player" in the breast cancer space, Fein tells investors in a...
$SGEN has been on a long-term bull run as we look at the weekly chart. Positive topline results signal that the bull run is set to continue and we expect $SGEN to keep racking up new 52-week highs.
Seattle Genetics (NASDAQ:SGEN) is up in reaction to positive results from a Phase 2 clinical trial, HER2CLIMB, evaluating combination of tucatinib, Roche's Herceptin...
Seattle Genetics, Inc. is a biotechnology company, which engages in the development and commercialization of antibody-based therapies for the treatment of cancer. Its products include Adcetris and Padcev. The firm is also advancing a pipeline of novel therapies for solid tumors and blood-related cancers. The company was founded by Clay B. Siegall and H. Perry Fell on July 15, 1997 and is headquartered in Bothell, WA.
SGEN
